2026-10-25
Mesa Laboratories, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
NAS100 29,403 −1.38%
S&P 7,720 −0.30%
GOLD $4,034 −0.44%
BTC $78,722 −3.13%
VIX 17.20 +1.71%
latest tape · as of 22:21 UTC · 29 Oct
The Screen · Technology
Mesa Laboratories, Inc.
MLAB · Nasdaq · USD · Market cap $706M
Not yet scored128.66 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 7 days ago
Screened 2026-10-23 · the tape above runs as of 22:21 UTC · 29 Oct · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price128.66 USD at the 23 Oct 2026 close
- Ethical screenNot yet scored
- Last reviewed23 Oct 2026 (7 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 128.66 against the desk's fair-value range, base estimate 125.00, over the last year.
- Trend Distribution
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options no verdict drawn today, left as found
- Ethical screen not yet scored
Price128.66 USD
Fair value125.00
Our investment reviews on this name
2026-10-20Read Distribution127.74+0.7% to today Markup gives way to Distribution after a 7% slide in 9 days
2026-10-11Read Markup137.50-6.4% to today Accumulation gives way to Markup first Markup read since September
2026-10-02Read Accumulation137.50-6.4% to today Markup gives way to Accumulation after a 36% rise in 8 weeks
2026-08-05Read Markup101.14+27.2% to today ✓Accumulation gives way to Markup with results news in the headlines
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
The full research record, in depth, below
This name holds its distribution label.
Mesa Laboratories, Inc. holds its Distribution at $128.66. Consolidating, no directional conviction, held for 5 days.
| Phase | Distribution · caution |
| Quantitative state | Consolidating, no directional conviction, held for 5 days |
| Price at the screen | $128.66 |
| Valuation | 148.42 trailing · 12.28 forward price to earnings |
| Values screen | Not scored |
| Beta | 1.05 |
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Permissible | Core business clean | Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. | Pass |
| Debt load | 28.37% | Below 33% | Interest-bearing debt is just 28.4% of its assets, well under the one-third ceiling: it does not run on borrowed money. | Pass |
| Interest-bearing cash | 5.08% | Below 33% | Cash held in interest-bearing accounts and securities is 5.1% of assets, under the one-third limit. | Pass |
| Receivables | 0.00% | Below 49% | Money owed to the company is 0.0% of assets, under the 49% limit. | Pass |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadThe Read, in Plain English
Mesa Laboratories, clears the business-activity screen and the figures we can measure look clean, but one or more financial figures are still pending, so the verdict is not final yet.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
2026-09-24
Clears
Mesa Laboratories, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 28%, inside the ~33% line, and almost none of its income is interest, so it passes.
Earlier reads, kept as written. The ethical profile is tracked over time, not overwritten.
What the Numbers Say It Is WorthThe Fair Value Range
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 2.8% above the base estimate.
Reading the gap · Our model and the Street both land near the screened price: fairly valued, with no strong edge either way.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words| Forward P/E | 12.3xexpensive even after accounting for its growth |
| Trailing P/E | 148.4xexpensive: the price assumes strong growth ahead |
| EPS, trailing | 0.85 |
| EPS, forward | 10.27 |
| Revenue growth | +1.0%slow but positive growth |
| Profit margin | 1.9%barely profitable |
| Return on equity | 2.7%a modest return on shareholder capital |
| FCF yield | 7.56% |
| Dividend yield | 59.00% |
| Debt to equity | 0.85moderate, manageable leverage |
| Current ratio | 1.79healthy short-term liquidity |
| Beta | 1.05moves a little more than the market |
| Short interest, float | 0.08% |
| 52-week range | 69.43 - 144.35 |
| Moat | WEAK |
| Market cap | $706M |
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeMLAB trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
2026-10-20
Distribution · changed $127.74
-7.1% Entry 8
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 7.1% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 20% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $104.
2026-10-11
Markup · changed $137.50
+0.0% Entry 7
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $104.
2026-10-02
Accumulation · changed $137.50
+14.9% Entry 6
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 14.9% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $104.
2026-09-05
Markup $119.72
+18.4% Entry 5
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.4% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $104.
2026-08-05
Markup · changed $101.14
-2.6% Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 2.6% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $104.
2026-07-18
Accumulation $103.89
+0.0% Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 30% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 5%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (2 analysts) rates it none, with a mean price target of $104.
2026-07-03
Accumulation $103.89
+0.0% Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
2026-07-02
Accumulation $103.89
Entry 1
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: PASS with ethical screening pending. The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth Yahoo Finance · 17d ago
- MESA LABS DECLARES QUARTERLY DIVIDEND Yahoo Finance · 20d ago
- Mesa Laboratories (MLAB) Q1 2027 Earnings Call Transcript Motley Fool · 17 Aug 2026
- Mesa Laboratories (MLAB) Q1 2027 Earnings Call Transcript Yahoo Finance · 17 Aug 2026
- Mesa Laboratories, Inc. Q1 2027 Earnings Call Summary Moby · 11 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
YALAYalla Group Limited
RSKDRiskified Ltd
ALITAlight Inc
SSYSStratasys Ltd.
CCSIConsensus Cloud Solutions Inc
YEXTYext Inc
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | TRIPENY R TONY | Director | 1,315 | $99,940 | |
| 2026-03-10 | CAPONE MARK CHRISTOPHER | Director | 1,301 | $99,331 | |
| 2026-03-10 | LADIWALA SHIRAZ SHABANALI | Director | 3,500 | $252,805 | |
| 2025-12-02 | SULLIVAN JOHN JAMES | Director | 2,000 | · | |
| 2025-10-27 | OWENS GARY M | Chief Executive Officer | 11,558 | · | |
| 2025-08-15 | HALL SHANNON | Director | 1,404 | · | |
| 2025-08-15 | LADIWALA SHIRAZ SHABANALI | Director | 1,949 | · | |
| 2025-08-15 | ALLTOFT JENNIFER SADIE | Director | 1,404 | · | |
| 2025-08-15 | SULLIVAN JOHN JAMES | Director | 1,404 | · | |
| 2025-08-15 | TRIPENY R TONY | Director | 1,404 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $102.73 | +5.5% | $0.16 | $1,057 | +5.7% |
| 2 months | $95.69 | +13.3% | $0.16 | $1,135 | +13.5% |
| 3 months | $77.69 | +39.6% | $0.16 | $1,398 | +39.8% |
| 6 months | $78.35 | +38.4% | $0.32 | $1,388 | +38.8% |
| 1 year | $103.56 | +4.7% | $0.64 | $1,053 | +5.3% |
| 2 years | $98.67 | +9.9% | $1.28 | $1,112 | +11.2% |
| 3 years | $128.61 | -15.7% | $1.92 | $858 | -14.2% |
| 5 years | $257.67 | -57.9% | $3.20 | $433 | -56.7% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever MLAB does next, these words stay.
Membership
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.